Abiopharma

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Stepan Increases Quarterly Cash Dividend, Marking the 58th Consecutive Year of Increases

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company

Bausch + Lomb Announces Third-Quarter 2025 Results

European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

Immunic to Participate in Industry and Investor Conferences in November

Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors

United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results